Probing RAS Function Using Monobody and NanoBiT Technologies.

Abstract excerpt

Missense mutations in the RAS family of oncogenes (HRAS, KRAS, and NRAS) are present in approximately 20% of human cancers, making RAS a valuable therapeutic target (Prior et al., Cancer Res 80:2969-2974, 2020). Although decades of research efforts to develop therapeutic inhibitors of RAS were unsuccessful, there has been success in recent years with the entrance of FDA-approved KRASG12C-specific inhibitors to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Communication
• Share to HRAS gene
• Share to NRAS gene